Portfolio

of candidate-antibiotics in development

DEINOVE builds a portfolio of first-in-class antibiotic candidates, which places it among the major players in the field, by bringing together a European network of expertise (Morphochem, Redx Pharma, bioMérieux, Naicons),

DEINOVE is preparing the entry into Phase II of a first antibiotic candidate targeting severe gastrointestinal infections caused by Clostridium difficile and is developing two early programs, including an anti Gram-negative program.

Anti-Gram Positive
Proprietary program

Severe Clostridium difficile infections

intravenous
Preclinical
Phase I
Phase II
Phase III
Anti-Gram negative
Licence option from REDX Pharma

HAD, cUTI, cIAI

Preclinical
Phase I
Phase II
Phase III
Anti-Gram positive
Proprietary program

New antibiotic structure

Preclinical
Phase I
Phase II
Phase III